A new direction in understanding the pathogenesis of respiratory syncytial virus bronchiolitis: How real infants suffer

Journal of Infectious Diseases

Volumn 195, Issue 8, 2007, Pages 1084-1086

  DeVincenzo, John P ^a,b  

^a UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

^b LE BONHEUR CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRONCHIOLITIS; EDITORIAL; HUMAN; IMMUNOPATHOGENESIS; INFANT; INFANT DISEASE; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; VIRUS IMMUNITY; VIRUS PATHOGENESIS;

BRONCHIOLITIS, VIRAL; HUMANS; INFANT; INFANT, NEWBORN; INFLUENZA, HUMAN; RECURRENCE; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS, HUMAN;

EID: 34047241251     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/512622     Document Type: Editorial

References (26)

1. Welliver TP, Garofalo RP, Hosakote Y, et al. Severe human lower respiratory tract illness caused by respiratory syncytial virus and influenza virus is characterized by the absence of pulmonary cytotoxic lymphocyte responses. J Infect Dis 2007; 195:1126-36 (in this issue).
2. Glezen WP, Taber LH, Frank AL, Kasel JA. Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child 1986; 140:543-6.
3. Shay DK, Holman RC, Newman RD, Liu LL, Stout JW, Anderson LJ. Bronchiolitis-associated hospitalizations among US children, 1980-1996. JAMA 1999; 282:1440-6.
4. Leader S, Kohlhase K. Respiratory syncytial virus-coded pediatric hospitalizations, 1997 to 1999. Pediatr Infect Dis J 2002; 21:629-32.
5. Djelantik IG, Gessner BD, Sutanto A, et al. Case fatality proportions and predictive factors for mortality among children hospitalized with severe pneumonia in a rural developing country setting. J Trop Pediatr 2003; 49:327-32.
6. Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003; 289:179-86.
7. Wang EE, Law BJ, Stephens D. Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) prospective study of risk factors and outcomes in patients hospitalized with respiratory syncytial viral lower respiratory tract infection. J Pediatr 1995; 126:212-9.
8. Boyce TG, Mellen BG, Mitchel EF Jr, Wright PF, Griffin MR. Rates of hospitalization for respiratory syncytial virus infection among children in Medicaid. J Pediatr 2000; 137:865-70.
9. Simoes EA. Respiratory syncytial virus and subsequent lower respiratory tract infections in developing countries: a new twist to an old virus. J Pediatr 1999; 135:657-61.
10. Howard TS, Hoffman LH, Stang PE, Simoes EA. Respiratory syncytial virus pneumonia in the hospital setting: length of stay, charges, and mortality. J Pediatr 2000; 137:227-32.
11. Kapikian A, Mitchell R, Chanock R, Shvedoff R, Stewart C. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am J Epidemiol 1969; 89:405-21.
12. Kim HW, Canchola JG, Brandt CD, et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 1969; 89:422-34.
13. Fulginiti V, Eller J, Sieber O, Joyner J, Minamitani M, Meiklejohn G. Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. Am J Epidemiol 1969; 89:435-48.
14. Graham BS, Johnson TR, Peebles RS. Immune-mediated disease pathogenesis in respiratory syncytial virus infection. Immunopharmacology 2000; 48:237-47.
15. Openshaw PJ, Tregoning JS. Immune responses and disease enhancement during respiratory syncytial virus infection. Clin Microbiol Rev 2005; 18:541-55.
16. Tripp RA. Pathogenesis of respiratory syncytial virus infection. Viral Immunol 2004; 17:165-81.
17. Legg JP, Hussain IR, Warner JA, Johnston SL, Warner JO. Type 1 and type 2 cytokine imbalance in acute respiratory syncytial virus bronchiolitis. Am J Respir Crit Care Med 2003; 168:633-9.
18. Aung S, Rutigliano JA, Graham BS. Alternative mechanisms of respiratory syncytial virus clearance in perforin knockout mice lead to enhanced disease. J Virol 2001; 75:9918-24.
19. Johnson JE, Gonzales RA, Olson SJ, Wright PF, Graham BS. The histopathology of fatal untreated human respiratory syncytial virus infection. Mod Pathol 2007; 20:108-19.
20. Buckingham SC, Jafri HS, Bush AJ, et al. A randomized, double-blind, placebo-controlled trial of dexamethasone in severe respiratory syncytial virus (RSV) infection: effects on RSV quantity and clinical outcome. J Infect Dis 2002; 185:1222-8.
21. DeVincenzo JP, El Saleeby CM, Bush AJ. Respiratory syncytial virus load predicts disease severity in previously healthy infants. J Infect Dis 2005; 191:1861-8.
22. Buckingham SC, Bush A, DeVincenzo JP. Nasal quantity of respiratory syncytial virus correlates with disease severity in hospitalized infants. Pediatr Infect Dis J 2000; 19:113-7.
23. DeVincenzo JP, El Saleeby CM, Bush AJ. Dynamics of RSV clearance predicts disease severity in infants. In: Program and abstracts of the VII International Symposium on Respiratory Viral Infections (Curacao, Netherlands Antilles). 2005.
24. El Saleeby CM, Suzich J, Conley ME, DeVincenzo JP. Quantitative effects of palivizumab and donor-derived T cells on chronic respiratory syncytial virus infection, lung disease, and fusion glycoprotein amino acid sequences in a patient before and after bone marrow transplantation. Clin Infect Dis 2004; 39:e17-20.
25. Schwarze J, O'Donnell DR, Rohwedder A, Openshaw PJ. Latency and persistence of respiratory syncytial virus despite T cell immunity. Am J Respir Crit Care Med 2004; 169:801-5.
26. Tripp RA. The brume surrounding respiratory syncytial virus persistence. Am J Respir Crit Care Med 2004; 169:778-9.